NO20082093L - Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser - Google Patents
Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaserInfo
- Publication number
- NO20082093L NO20082093L NO20082093A NO20082093A NO20082093L NO 20082093 L NO20082093 L NO 20082093L NO 20082093 A NO20082093 A NO 20082093A NO 20082093 A NO20082093 A NO 20082093A NO 20082093 L NO20082093 L NO 20082093L
- Authority
- NO
- Norway
- Prior art keywords
- protein kinases
- pyrazole
- inhibition
- pyrimidine derivatives
- kinase
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title abstract 3
- 108060006633 protein kinase Proteins 0.000 title abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72415805P | 2005-10-06 | 2005-10-06 | |
PCT/US2006/038917 WO2007044441A2 (fr) | 2005-10-06 | 2006-10-04 | Methodes destinees a inhiber des proteines kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082093L true NO20082093L (no) | 2008-07-03 |
Family
ID=37943366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082093A NO20082093L (no) | 2005-10-06 | 2008-05-05 | Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser |
Country Status (11)
Country | Link |
---|---|
US (2) | US20070082900A1 (fr) |
EP (1) | EP1942900B1 (fr) |
JP (3) | JP5152922B2 (fr) |
CN (1) | CN101360499B (fr) |
BR (1) | BRPI0616985B1 (fr) |
CA (1) | CA2627623C (fr) |
NO (1) | NO20082093L (fr) |
NZ (1) | NZ567151A (fr) |
TW (1) | TWI421078B (fr) |
WO (1) | WO2007044441A2 (fr) |
ZA (1) | ZA200802998B (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
EP1945216A1 (fr) * | 2005-11-10 | 2008-07-23 | Schering Corporation | Méthodes d'inhibition de protéine kinases |
CA2643362A1 (fr) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Utilisation de derives de pyrazolo[1,5a]pyrimidin-7-yl amine dans le traitement de troubles neurologiques |
BRPI0712016A2 (pt) * | 2006-05-22 | 2011-12-27 | Schering Corp | pirazolo[1,5-a]pirimidinas |
JP2010510222A (ja) * | 2006-11-17 | 2010-04-02 | シェーリング コーポレイション | 増殖性障害に対する併用療法 |
TW200845962A (en) | 2007-05-08 | 2008-12-01 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
US20120029204A1 (en) * | 2007-06-07 | 2012-02-02 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
AR069198A1 (es) * | 2007-11-07 | 2010-01-06 | Schering Corp | Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer. |
AU2008343932B2 (en) * | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
EP2242755B1 (fr) | 2008-01-08 | 2012-09-12 | Array Biopharma, Inc. | Pyrrolopyridines en tant qu'inhibiteurs de kinase |
ES2392014T3 (es) * | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
MX2010010975A (es) * | 2008-04-07 | 2010-11-01 | Amgen Inc | Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular. |
AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
PL3372605T3 (pl) * | 2008-10-22 | 2022-03-07 | Array Biopharma Inc. | Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk |
KR101686685B1 (ko) * | 2008-10-31 | 2016-12-14 | 제넨테크, 인크. | 피라졸로피리미딘 jak 억제제 화합물 및 방법 |
KR20110114663A (ko) | 2009-02-13 | 2011-10-19 | 바이엘 파마 악티엔게젤샤프트 | 융합된 피리미딘 |
WO2010118207A1 (fr) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Dérivés pyrazolo[1, 5-a]pyrimidine en tant qu'inhibiteurs de mtor |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP2473041B1 (fr) | 2009-09-04 | 2018-03-07 | Merck Sharp & Dohme Corp. | Modulateurs de points de contrôle du cycle cellulaire et leur utilisation en combinaison avec des inhibiteurs de kinase de point de contrôle |
SG179083A1 (en) * | 2009-09-11 | 2012-04-27 | Cylene Pharmaceuticals Inc | Pharmaceutically useful heterocycle-substituted lactams |
DK2521776T3 (en) * | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
CA2786377C (fr) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions et methodes de traitement de gliomes malins employant des vecteurs viraux codant un fas-chimere |
EP2525659B1 (fr) * | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | COMPOSÉS PYRAZOLO[1,5-a]PYRIMIDINES EN TANT QU'INHIBITEURS DE mTOR |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
EP2734520B1 (fr) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
EP2755482B1 (fr) | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combinaison de mk-1775 et mk-8776 pour le traitement du cancer |
JP6377068B2 (ja) | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
EP3808749B1 (fr) | 2012-12-07 | 2023-03-08 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines utiles en tant qu'inhibiteurs de kinase d'atr pour le traitement des maladies de cancer |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2014143241A1 (fr) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP6095857B2 (ja) * | 2013-11-15 | 2017-03-15 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
EP3087069B1 (fr) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Composés utiles en tant que modulateurs du ccr9 |
GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP3152212B9 (fr) | 2014-06-05 | 2020-05-27 | Vertex Pharmaceuticals Inc. | Dérivés radiomarqués d'un composé 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]-pyrazolo[1,5-a]pyrimidine-3-carboxamide utile comme inhibiteur de la kinase atr, préparation dudit composé, et différentes formes solides associées |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
FI3699181T3 (fi) | 2014-11-16 | 2023-03-28 | Array Biopharma Inc | Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
GB201517263D0 (en) * | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MA44610A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
PT3800189T (pt) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
AR110252A1 (es) * | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
JP7216705B2 (ja) | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用方法 |
EP3461480A1 (fr) | 2017-09-27 | 2019-04-03 | Onxeo | Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer |
AU2019360941A1 (en) * | 2018-10-15 | 2021-04-29 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
US11155560B2 (en) | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
CA3122136A1 (fr) * | 2018-12-07 | 2021-06-11 | Betta Pharmaceuticals Co., Ltd | Inhibiteurs de tyrosine kinase, compositions et procedes associes |
JP2022529311A (ja) | 2019-03-26 | 2022-06-21 | ベンティックス バイオサイエンシーズ,インク. | Tyk2偽キナーゼリガンド |
IL292785A (en) | 2019-11-08 | 2022-07-01 | Ventyx Biosciences Inc | tyk2 pseudokinase ligands |
JP7254246B2 (ja) | 2019-11-25 | 2023-04-07 | アムジエン・インコーポレーテツド | デルタ-5デサチュラーゼ阻害剤としての複素環式化合物及び使用方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0438730Y2 (fr) * | 1986-03-26 | 1992-09-10 | ||
JP3039751U (ja) * | 1996-12-09 | 1997-07-31 | 尚子 小園 | 鞄類用補助具 |
JP2002295682A (ja) * | 2001-03-28 | 2002-10-09 | Yazaki Corp | 防水構造およびこの防水構造に用いられる座金部材 |
MXPA04012245A (es) * | 2002-06-04 | 2005-09-30 | Neogenesis Pharmaceuticals Inc | Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales. |
US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
JP4881558B2 (ja) * | 2002-09-04 | 2012-02-22 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
NZ539162A (en) * | 2002-09-04 | 2006-07-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2004215481B2 (en) * | 2003-02-28 | 2010-11-11 | Teijin Pharma Limited | Pyrazolo(1,5-A)pyrimidine derivatives |
US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
JP3940700B2 (ja) * | 2003-05-22 | 2007-07-04 | 茂 相馬 | 楽器用ケース |
PE20051089A1 (es) * | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
JP3104094U (ja) * | 2004-03-18 | 2004-09-02 | チャン ホアン−リン | 両用スーツケース |
JP2009511484A (ja) * | 2005-10-06 | 2009-03-19 | シェーリング コーポレイション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
AR056206A1 (es) * | 2005-10-06 | 2007-09-26 | Schering Corp | Pirazolpirimidinas como inhibidores de protein quinasas |
JP3174645U (ja) * | 2012-01-19 | 2012-03-29 | 株式会社セイバン | ランドセル |
-
2006
- 2006-10-04 TW TW095136818A patent/TWI421078B/zh not_active IP Right Cessation
- 2006-10-04 EP EP06836185.6A patent/EP1942900B1/fr active Active
- 2006-10-04 JP JP2008534673A patent/JP5152922B2/ja active Active
- 2006-10-04 BR BRPI0616985-6A patent/BRPI0616985B1/pt active IP Right Grant
- 2006-10-04 NZ NZ567151A patent/NZ567151A/en not_active IP Right Cessation
- 2006-10-04 CA CA2627623A patent/CA2627623C/fr active Active
- 2006-10-04 US US11/542,801 patent/US20070082900A1/en not_active Abandoned
- 2006-10-04 CN CN200680045935.5A patent/CN101360499B/zh active Active
- 2006-10-04 WO PCT/US2006/038917 patent/WO2007044441A2/fr active Application Filing
-
2008
- 2008-04-04 ZA ZA200802998A patent/ZA200802998B/xx unknown
- 2008-05-05 NO NO20082093A patent/NO20082093L/no not_active Application Discontinuation
-
2010
- 2010-01-15 US US12/688,664 patent/US8211854B2/en active Active
-
2012
- 2012-01-27 JP JP2012015831A patent/JP5520325B2/ja active Active
-
2014
- 2014-01-09 JP JP2014002164A patent/JP2014062129A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1942900B1 (fr) | 2015-06-03 |
CN101360499A (zh) | 2009-02-04 |
TWI421078B (zh) | 2014-01-01 |
BRPI0616985A2 (pt) | 2009-08-04 |
CA2627623C (fr) | 2014-04-22 |
ZA200802998B (en) | 2009-10-28 |
JP2014062129A (ja) | 2014-04-10 |
JP5520325B2 (ja) | 2014-06-11 |
JP5152922B2 (ja) | 2013-02-27 |
CN101360499B (zh) | 2015-10-07 |
BRPI0616985B1 (pt) | 2021-10-26 |
NZ567151A (en) | 2012-03-30 |
JP2012082234A (ja) | 2012-04-26 |
TW200800218A (en) | 2008-01-01 |
JP2009511486A (ja) | 2009-03-19 |
US8211854B2 (en) | 2012-07-03 |
AU2006302435A1 (en) | 2007-04-19 |
WO2007044441A2 (fr) | 2007-04-19 |
WO2007044441A3 (fr) | 2007-07-26 |
US20070082900A1 (en) | 2007-04-12 |
EP1942900A2 (fr) | 2008-07-16 |
CA2627623A1 (fr) | 2007-04-19 |
US20100125068A1 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082093L (no) | Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser | |
MXPA06010904A (es) | Inhibidores de pirazol cinasa triciclicos. | |
NO20082091L (no) | Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer | |
NO20082092L (no) | Pyrazolopyrimidiner som proteinkinaseinhibitorer | |
NO20072795L (no) | Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser | |
DE602007013441D1 (de) | Pyrazolopyrimidine als pi3k-lipidkinasehemmer | |
NO20064046L (no) | Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer | |
MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
WO2007079164A3 (fr) | Inhibiteurs de protéines kinases | |
WO2006124354A3 (fr) | Inhibiteurs de la tyrosine kinase | |
WO2008083367A3 (fr) | Triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs de axl | |
WO2007041358A3 (fr) | Composes pyrazole substitues | |
MX2009003734A (es) | Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina. | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
HK1112233A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer | |
MX2010006203A (es) | Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina. | |
TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
GEP20125368B (en) | Kinase inhibitors | |
MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
MX2009011810A (es) | Tiazoles y pirazoles utiles como inhibidores de cinasa. | |
MX2009003733A (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. | |
WO2007113212A3 (fr) | Utilisation d'un inhibiteur de la kinase pour traiter des tumeurs résistantes spécifiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP, US Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |